The Rosen Law Firm, P.A. announces that it has filed a class action lawsuit on behalf of purchasers of Insys Therapeutics Inc (NASDAQ:INSY) securities between May 1, 2013 and May 8, 2014, seeking to recover damages for violations of the federal securities laws. Insys Therapeutics Inc (NASDAQ:INSY) net profit margin is 40.60% and weekly performance is -27.02%. On last trading day company shares ended up $23.85. Analysts mean target price for the company is $62.00. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -41.27%.
On May 8, ArQule, Inc. (NASDAQ:ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share. The company had reported a loss of 9 cents in the year-ago quarter. Revenues plummeted 52.7% to $2.7 million in the first quarter of 2014, but surpassed the Zacks Consensus Estimate of $2 million. ArQule, Inc. (NASDAQ:ARQL) shares fell -2.01% in last trading session and ended the day on $1.46. ARQL return on assets is -22.30%. ArQule, Inc. (NASDAQ:ARQL) quarterly performance is -33.94%.
May 12, 2014 TrovaGene Inc (NASDAQ:TROV) reported its financial results for the three months ended March 31, 2014. For the first quarter ended March 31, 2014, Trovagene reported a net loss of $3.2 million, or $0.17 per share, as compared to a net loss of $1.1 million, or $0.07 per share, for the three months ended March 31, 2013. The increase in net loss is primarily due to increased operating expenses and changes in the fair market value of derivative instruments during the first quarter of 2014 as compared to the prior year comparable period. TrovaGene Inc (NASDAQ:TROV) shares moved down -3.19% in last trading session and was closed at $3.95, while trading in range of $3.49 – $4.04. TrovaGene Inc (NASDAQ:TROV) year to date (YTD) performance is -31.18%.
On May 14, 2014, Transcept Pharmaceuticals Inc (NASDAQ:TSPT) announced that its board of directors declared a special cash dividend of $1.33 per share on the Company’s common stock. Payment will be made on June 3, 2014, to stockholders of record at the close of business on May 26, 2014. Transcept Pharmaceuticals Inc (NASDAQ:TSPT) ended the last trading day at $3.09. Company weekly volatility is calculated as 2.54% and price to cash ratio as 0.83. Transcept Pharmaceuticals Inc (NASDAQ:TSPT) showed a positive weekly performance of 5.46%.
Leave a Reply